Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ex-Chief Of Europe's Regulatory Agency To Be Kept On A Tight Rein

This article was originally published in The Pink Sheet Daily

Executive Summary

Former executive director of the European Medicines Agency, Thomas Lönngren, told to limit his pharmaceutical industry roles; FDA Commissioners have it easier.

You may also be interested in...



European Notebook: EMA Conflict Of Interest Rules; EU Unitary Patent; EMA Adverse Event Literature Screening

EMA tightens rules on the revolving door between industry and scientific (if not regulators); the European unitary patent proposal survives Spain's judicial challenge; Switzerland amends its drug pricing procedures, and more in this month's column.

Europe Transparency Initiatives May Aid Progress Toward Adaptive Licensing Systems

Industry and regulators are showing more interest in implementing adaptive licensing in Europe. Both sides agree that increased trust and transparency could be stepping stones towards this goal.

European Generics Applications Fall, As EMA’s Interim Report Hopes To Herald Funding Renewal

European Commission intervention has stopped duplicate generic applications. EMA hopes to end its budget row with the EU Parliament by focusing on transparency and conflict of interest disclosures.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel